Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Regenerative medicine: are we there yet?

Despite almost 2500 clinical trials involving stem cells, there is not a single clinical problem that is routinely treated with stem cell therapy because it is better than the standard of care. For all the progress we have made in the fast moving field of regenerative medicine, the capacity to routinely restore functional tissue following traumatic injury or degenerative disease is still beyond reach.

Have the technologies that we now have at hand, such as 3-D printing, deep genomic sequencing and manipulation, or directed stem cell differentiation in the dish, outpaced our understanding of the signals that orchestrate natural development? Should we attempt to restore the epimorphic regeneration potential of humans, releasing the newt within us? Is it even possible to restore a non-blastemal regeneration response in organs like the human brain? It is tempting to extrapolate from the remarkable regenerative capacity of the mammalian neonate and envision the engineering of a similar response in the adult. Or perhaps we should be satisfied with moving the needle from the default inflammation/scar tissue formation response toward a more constructive and functional response, and leave true regeneration to “more primitive” species such as the newt until we understand the upstream signals that regulate these processes.

To advance the pace of progress, scientists are now adopting multidisciplinary strategies, combining evolutionarily conserved principles of developmental biology, immunology, stem cell biology, tissue engineering, biomechanics, and medicine in ex vivo and in vivo approaches. Recreating the supportive micro-environment of a regenerating zebrafish heart in a patient will require a more profound understanding of the 30% differences in protein coding genes between fish and man, and dynamic cellular processes that rapidly modulate immune response to bypass the physical blockade of infarct scar, promote revascularization to prevent more cell death, and provide the necessary extracellular milieu for restoration of functional cardiac contractile tissue. We’re not there yet, but there’s promising light on the horizon.


Competing interests

The authors declare no conflict of interest.

Author information



Corresponding author

Correspondence to Nadia Rosenthal.

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Badylak, S., Rosenthal, N. Regenerative medicine: are we there yet?. npj Regen Med 2, 2 (2017).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing